{"id":"W3047400464","doi":"10.1016/j.annonc.2020.07.001","title":"The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No","year":2020,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Arnold Ventures; Roche; Takeda Pharmaceuticals U.S.A.; Pfizer","keywords":"Medicine; Pembrolizumab; Crizotinib; Nivolumab; Ipilimumab; Oncology; Family medicine; Internal medicine; Lung cancer; Cancer; Immunotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01440703,0.0005037577,0.001188553,0.0007661909,0.00257271,0.004656781,0.001648281,0.01913636,0.01800301],"category_scores_gemma":[0.04657007,0.0005557834,0.001545549,0.0005924606,0.004277073,0.006055363,0.001566857,0.02192617,0.01161994],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003278592,"about_ca_system_score_gemma":0.004645813,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00236643,"about_ca_topic_score_gemma":0.006578005,"domain_scores_codex":[0.991658,0.002806805,0.0007649025,0.0009584539,0.003063902,0.0007479029],"domain_scores_gemma":[0.9787355,0.009030508,0.001803812,0.0007901471,0.00528105,0.004358971],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002981755,0.00004312475,0.0003723565,0.0001638761,0.00004033339,0.000197248,0.00005473296,0.00004379664,0.0003695046,0.007491969,0.929352,0.06157281],"study_design_scores_gemma":[0.0003230221,0.0002350435,0.0007549901,0.001025119,0.00010605,0.0005265993,0.0002247252,0.0002026032,0.0006248129,0.01444381,0.9814411,0.00009209863],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0008229812,0.009023488,0.000526419,0.9614936,0.02184573,0.00002391553,0.0001932452,0.00006564674,0.006004863],"genre_scores_gemma":[0.01408906,0.01042982,0.002145902,0.9343817,0.02516652,0.00006495986,0.0002736955,0.0001106009,0.01333776],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.01913636,"threshold_uncertainty_score":0.07619256,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07303249655138225,"score_gpt":0.4114210955109136,"score_spread":0.3383885989595313,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}